ArticleFrontiers in veterinary science2025
Tocilizumab binds to canine IL-6 receptor and elicits
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anti-inflammatory, analgesic, and anti-immune-mediated polyarthritis activities of topically applied polarity fractions ofFrontiers in veterinary science · 2026Article
- Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tocilizumab (TCZ) is an immunosuppressive drug approved for the treatment of rheumatoid arthritis in humans. Molecularly, it is a humanized monoclonal antibody (mAb) that binds to the interleukin-6 receptor (IL-6R), blocking its inflammatory pathway with the IL-6 protein. A previous study has looked at the safety of topical TCZ as eye drops in dogs, however, no studies have tested its potential use in canine diseases based on species antibody differences. Materials and methods: (1) To assess the biological inhibitory effect of TCZ on canine macrophages Results: Our results confirm binding of TCZ with canine IL-6R. In comparison, canine IL-6R binds two orders of magnitude less than human IL-6R in its dissociation constant. Canine cell culture required a higher concentration of TCZ compared to human cell culture to produce a similar inhibitory effect. Conclusions and clinical significance: The binding of TCZ to canine IL-6R resulting in a biological response is a specific example of the new possibilities to harness humanized mAb for canine diseases. TCZ may not be a feasible treatment due to the binding affinity and the high concentrations needed. However, future studies should explore potential suitable human mAb for treating canine autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.